vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and FVCBankcorp, Inc. (FVCB). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $16.9M, roughly 1.1× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -25.7%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-15.8M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
CTMX vs FVCB — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $16.9M |
| Net Profit | $-154.0K | — |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 43.7% |
| Net Margin | -0.8% | — |
| Revenue YoY | -25.7% | 4377.5% |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $16.9M | ||
| Q3 25 | — | $416.0K | ||
| Q2 25 | $18.7M | $15.8M | ||
| Q1 25 | $50.9M | $382.0K | ||
| Q4 24 | $38.1M | $378.0K | ||
| Q3 24 | $33.4M | $412.0K | ||
| Q2 24 | $25.1M | $415.0K | ||
| Q1 24 | $41.5M | $359.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $5.6M | ||
| Q2 25 | $-154.0K | $5.7M | ||
| Q1 25 | $23.5M | $5.2M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $4.7M | ||
| Q2 24 | $-6.5M | $4.2M | ||
| Q1 24 | $13.8M | $1.3M |
| Q4 25 | — | 43.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | 45.9% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1341.1% | ||
| Q2 25 | -0.8% | 36.0% | ||
| Q1 25 | 46.2% | 1352.1% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 1133.3% | ||
| Q2 24 | -26.0% | 1001.2% | ||
| Q1 24 | 33.3% | 373.3% |
| Q4 25 | — | $0.31 | ||
| Q3 25 | — | $0.31 | ||
| Q2 25 | — | $0.31 | ||
| Q1 25 | — | $0.28 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | — | $0.25 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | — | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $253.6M |
| Total Assets | $175.1M | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $253.6M | ||
| Q3 25 | — | $249.8M | ||
| Q2 25 | $119.9M | $243.2M | ||
| Q1 25 | $25.0M | $242.3M | ||
| Q4 24 | $-456.0K | $235.4M | ||
| Q3 24 | $-23.5M | $230.8M | ||
| Q2 24 | $-31.2M | $226.5M | ||
| Q1 24 | $-31.7M | $220.7M |
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | $175.1M | $2.2B | ||
| Q1 25 | $98.5M | $2.2B | ||
| Q4 24 | $120.5M | $2.2B | ||
| Q3 24 | $139.0M | $2.3B | ||
| Q2 24 | $159.2M | $2.3B | ||
| Q1 24 | $184.7M | $2.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $23.9M |
| Free Cash FlowOCF − Capex | $-15.8M | $23.8M |
| FCF MarginFCF / Revenue | -84.6% | 140.7% |
| Capex IntensityCapex / Revenue | 0.1% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $40.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $23.9M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-15.8M | $3.3M | ||
| Q1 25 | $-21.0M | $5.4M | ||
| Q4 24 | $-19.9M | $18.2M | ||
| Q3 24 | $-20.7M | $4.7M | ||
| Q2 24 | $-19.5M | $1.6M | ||
| Q1 24 | $-26.0M | $7.2M |
| Q4 25 | — | $23.8M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-15.8M | $3.3M | ||
| Q1 25 | $-21.2M | $5.4M | ||
| Q4 24 | $-20.0M | $18.1M | ||
| Q3 24 | $-20.7M | $4.6M | ||
| Q2 24 | $-19.6M | $1.5M | ||
| Q1 24 | $-26.2M | $7.1M |
| Q4 25 | — | 140.7% | ||
| Q3 25 | — | 1818.0% | ||
| Q2 25 | -84.6% | 20.8% | ||
| Q1 25 | -41.6% | 1413.6% | ||
| Q4 24 | -52.5% | 4786.0% | ||
| Q3 24 | -62.1% | 1121.8% | ||
| Q2 24 | -78.2% | 361.2% | ||
| Q1 24 | -63.1% | 1988.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 0.2% | 4.2% | ||
| Q4 24 | 0.2% | 37.3% | ||
| Q3 24 | 0.1% | 14.1% | ||
| Q2 24 | 0.4% | 12.8% | ||
| Q1 24 | 0.3% | 3.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | -0.89× | 1.05× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 1.00× | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | -1.89× | 5.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FVCB
Segment breakdown not available.
